🧪 TrialInsufficient
Registered Phase 2 interventional trial (completed). This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once weekly for 28 weeks. If an individual is randomly assigned to MET097 they will receive one of four different dose regimens.
ClinicalTrials.gov · Mar 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 4 interventional trial (recruiting). The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
ClinicalTrials.gov · Mar 2025View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (active not recruiting). This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
ClinicalTrials.gov · Mar 2025View trial ↗ Insufficient
This entry reviews the available information on bremelanotide, a cyclic peptide (molecular weight ~1025 Da), specifically in the context of breastfeeding safety. The review notes a complete absence of published clinical data on bremelanotide use during lactation. The authors reason that, based on its physicochemical properties as a large cyclic peptide, transfer into breast milk is theoretically expected to be minimal. Furthermore, even if trace amounts were present in milk, oral absorption by a nursing infant would likely be negligible, as the peptide would probably be degraded by proteolytic enzymes in the infant's gastrointestinal tract. Despite this theoretical reassurance, the review concludes that caution is warranted during breastfeeding due to the lack of empirical data, with particular emphasis on vulnerability in newborn and preterm infants, whose gastrointestinal and hepatic systems are less mature. The primary limitation of this entry is that it is entirely inference-based, drawing on pharmacokinetic principles rather than any direct human or animal lactation studies. No measured milk concentration data, infant outcome data, or controlled observations are cited.
Unknown journal · Feb 2025Source ↗ 🧪 TrialInsufficient
Registered Phase 4 interventional trial (active not recruiting). This study is being done to assess the efficacy of a saliva- based biomarker to predict response to semaglutide for the treatment of obesity.
ClinicalTrials.gov · Feb 2025View trial ↗ Insufficient
This entry corresponds to a withdrawn article originally submitted to the journal Current Neuropharmacology, investigating the use of the stable gastric pentadecapeptide BPC 157 as a potential therapy for severe electrolyte disturbances in rats. The article was retracted at the authors' own request, and the publisher (Bentham Science) provided no details regarding the specific findings, data, or conclusions of the original study. Because the full content of the paper is unavailable — replaced entirely by a withdrawal notice — no experimental methods, results, or conclusions can be evaluated or attributed to the study. The withdrawal notice also includes standard publisher boilerplate regarding submission conditions and plagiarism policy, but does not disclose the reason for withdrawal. As a result, this record cannot be used to draw any conclusions about BPC 157's effects on electrolyte disturbances. Researchers and educators should treat this citation as non-existent in the evidence base, as the underlying data and claims are no longer accessible or endorsed by the authors or publisher.
Current neuropharmacology · Jan 2025DOI ↗ Insufficient
This cross-sectional pilot study examined the direct-to-consumer market for compounded glucagon-like peptide-1 (GLP-1) receptor agonists in Colorado. Researchers conducted Google searches of business websites advertising compounded GLP-1 products for weight loss across census-defined statistical areas between March and April 2024. They identified 93 websites corresponding to 188 physical locations. Most businesses were categorized as medical/health spas or weight loss services. Semaglutide was the most commonly advertised product (92/93 sites), followed by tirzepatide (40/93). Some sites advertised combination formulations including B vitamins, BPC-157 (flagged by the FDA as unsafe for compounding), and other additives. Seven sites advertised oral formulations. Notably, 41 of 93 websites referenced FDA approval in their product descriptions—a potentially misleading claim, as compounded products are not FDA-approved—and 5 sites incorrectly referred to products as "generic." The study's limitations include its focus on a single state, reliance on publicly available website data, and its pilot/cross-sectional design, which limits generalizability. The authors conclude that regulatory action is needed to address misleading advertising and safety concerns in this market.
Journal of pharmaceutical policy and practice · Dec 2024DOI ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (active not recruiting). The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
ClinicalTrials.gov · Oct 2024View trial ↗ Insufficient
SYNCHRONIZE-CVOT is a phase 3, randomized, double-blind, placebo-controlled, event-driven cardiovascular (CV) outcomes trial evaluating survodutide — a dual glucagon and GLP-1 receptor agonist administered subcutaneously once weekly — in adults with obesity or overweight (BMI ≥27 kg/m²) who also have established CV disease, chronic kidney disease, and/or at least two weight-related complications or CV risk factors. The primary endpoint is time to first occurrence of a 5-point major adverse cardiovascular event (MACE) composite. The trial targets enrollment of 4,935 participants globally and is currently in the recruitment phase (NCT06077864). The paper describes the scientific rationale — that dual glucagon/GLP-1 receptor agonism may produce greater weight reduction than GLP-1 agonism alone — and outlines the trial design in detail. As a design/rationale publication, no efficacy or safety outcomes are yet available. Key limitations at this stage include the absence of results and the event-driven nature meaning the timeline is uncertain. This trial will be the first to formally assess CV safety and potential efficacy of survodutide in a high-risk obesity population.
JACC. Heart failure · Oct 2024DOI ↗ Insufficient
This forensic laboratory study describes the analytical challenges encountered when identifying Melanotan II — a synthetic peptide informally nicknamed the "Barbie drug" — in suspected illicit drug samples submitted for analysis. Researchers used HPLC-DAD, UHPLC-TOF-MS, and UPLC-MS/MS to characterize a powder found in pharmaceutical-appearing vials labeled "Melanotan II." Standard library searches via HPLC-DAD yielded no match, partly because the UV spectrum for Melanotan II was not available in the reference library at the time. Mass spectrometric identification was further complicated by the peptide's relatively high molecular weight (~1024 Da), which exceeded the typical detection ceiling of instruments configured for classical small-molecule drugs of abuse, and by the compound's multi-charged ionization behavior. Using a reference standard, the team ultimately confirmed the identity of Melanotan II and estimated a purity of approximately 30%. The study highlights that Melanotan II is not approved for market use due to safety concerns and is sold illicitly primarily for skin tanning. The authors suggest that the significant analytical hurdles involved in detecting this peptide may partly explain its growing presence on the illicit market. This study is a descriptive forensic case report with no clinical outcome data or human subject testing.
Journal of forensic sciences · Sep 2024DOI ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (completed). The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up per
ClinicalTrials.gov · Sep 2024View trial ↗ 🧪 TrialInsufficient
Registered Phase 2 interventional trial (recruiting). People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and more rapid development of frailty, a multisystemic syndrome of aging characterized by reduced activity, fatigue, slowness, weakness, and weight loss. While exercise can improve physical function in people with HIV, it is less effective in doing so than in the general population and is difficult to sustain in the long-term. The goal of this clinical trial is to learn whether the medic
ClinicalTrials.gov · Aug 2024View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (active not recruiting). This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.
ClinicalTrials.gov · Aug 2024View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (active not recruiting). The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
ClinicalTrials.gov · Apr 2024View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (completed). The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.
ClinicalTrials.gov · Apr 2024View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (active not recruiting). The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
ClinicalTrials.gov · Feb 2024View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (completed). This is a multicenter, randomized, Open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 6 mg OW versus Semalgutide 1 mg OW in obese(BMI≥28kg/m2) early T2D subjects. Subjects will be randomly assigned to IBI362 6 mg and Semalgutide 1 mg groups for 32 weeks (active-controlled treatment period). In the extension period, participants originally on mazdutide were assigned to continue for an additional 24 weeks with mazdutide 9 mg or 6 mg based on whether they achieved the weight-loss target. All study treatment will be ad
ClinicalTrials.gov · Dec 2023View trial ↗ Insufficient
This study, conducted by a doping control laboratory, describes the development and analytical validation of a method for detecting growth hormone-releasing hormones (GHRHs) — specifically tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH₂, and somatorelin — in human urine samples. GHRHs are prohibited in sport under World Anti-Doping Agency (WADA) regulations. The method combines weak cation exchange solid-phase extraction (SPE) with ultra-high-performance liquid chromatography coupled to triple quadrupole tandem mass spectrometry (UHPLC-MS/MS). The researchers validated the method according to WADA technical documents, evaluating selectivity, limit of detection (LOD), carryover, reliability, stability, and recovery. The method achieved an LOD of 0.2 ng/mL, a limit of quantification (LOQ) of 0.6 ng/mL, and linearity from 0.1 to 1.2 ng/mL. The study reports adequate recovery and sensitivity for routine anti-doping screening. A key limitation is that this is purely an analytical/method-development study; it does not investigate pharmacological effects, clinical outcomes, or administer any compound to human or animal subjects.
Analytical biochemistry · Oct 2023DOI ↗ 🧪 TrialInsufficient
Registered Phase 2 interventional trial (completed). A multicenter randomized double-blind placebo parallel control design was used in this study. The 90 participants were randomly assigned to placebo, 0.5μg/kg dose group, and 1.0μg/kg dose group in a ratio of 1:1:1. After randomization, subjects received the trial drug or placebo intravenously within 12 hours and on days 2 to 7 after PCI. The patients were observed 90 days after PCI.
ClinicalTrials.gov · Aug 2023View trial ↗ 🧪 TrialInsufficient
Registered Phase 3 interventional trial (active not recruiting). The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
ClinicalTrials.gov · Jul 2023View trial ↗